ARCH Venture Partners IX, LLC - Jun 21, 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: 10%+ Owner
Signature: /s/ ARCH Venture Fund IX, L.P., By: ARCH Venture Partners IX, L.P., its General Partner, By: ARCH Venture Partners IX, LLC, its General Partner, By: Mark McDonnell, attorney in-fact
Stock symbol: LYEL
Transactions as of: Jun 21, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/23/2021, 05:42 PM
Previous filing: Jun 16, 2021
Next filing: Jun 24, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Conversion of derivative security		+18.2M			18.2M	Jun 21, 2021	ARCH Venture Fund IX, L.P.	F1, F2
transaction	LYEL	Common Stock	Conversion of derivative security		+18.2M			18.2M	Jun 21, 2021	ARCH Venture Fund IX Overage, L.P.	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	LYEL	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-17.8M	-100%	$0.00^*	Jun 21, 2021	Common Stock	17.8M	ARCH Venture Fund IX, L.P.	F1, F2
transaction	LYEL	Series A Convertible Preferred Stock	Conversion of derivative security	$0	-17.8M	-100%	$0.00^*	Jun 21, 2021	Common Stock	17.8M	ARCH Venture Fund IX Overage, L.P.	F1, F2
transaction	LYEL	series C Convertible Preferred Stock	Conversion of derivative security	$0	-435K	-100%	$0.00^*	Jun 21, 2021	Common Stock	435K	ARCH Venture Fund IX, L.P.	F1, F2
transaction	LYEL	Series C Convertible Preferred Stock	Conversion of derivative security	$0	-435K	-100%	$0.00^*	Jun 21, 2021	Common Stock	435K	ARCH Venture Fund IX Overage, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Issuer's Series A Convertible Preferred Stock and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.
F2	ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

Content

The Issuer's Series A Convertible Preferred Stock and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date.

ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to the extent of any pecuniary interest therein.